Opus Genetics (IRD) Reiterated at Market Outperform by Citizens: Focus on Viatris

August 28, 2026 4:42 AM

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $12.00 price target on Opus Genetics (NASDAQ: IRD).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found